Making sense of genetic gray areas. The American College of Medical Genetics and Genomics (ACMG) has released new guidance on how labs and clinicians should report variants of uncertain significance (VUS) — genetic changes whose disease links remain unclear. The statement pushes for greater consistency and transparency, including a new distinction between VUS more likely to turn out benign versus those warranting closer clinical follow-up.
Making sense of genetic gray areas
The American College of Medical Genetics and Genomics (ACMG) has published a landmark guidance statement on reporting variants of uncertain significance (VUS) — genetic changes for which there's currently not enough evidence to confirm or rule out a disease link. As genetic testing becomes more common in clinical care, VUS results have been a persistent source of confusion for both patients and providers.
The new statement, published in Genetics in Medicine, calls for standardized, transparent reporting practices across all clinical laboratories. A key recommendation is distinguishing between VUS-low (variants more likely to be reclassified as benign) and VUS-high (variants that may warrant more active clinical follow-up) — a nuance that could meaningfully shape how clinicians respond to uncertain results.
Key Takeaways
Why it matters: With genetic testing expanding rapidly, ambiguous results can lead to unnecessary anxiety, over-testing, or missed follow-up. Standardized VUS reporting gives clinicians and patients a clearer roadmap for navigating uncertainty.
